Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 0.51 |
| ▸ | DHODH | Q02127 | 8/20 | 0.48 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.40 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10190510 | 0.86 | S1PR1 (0.53) | S1PR1DHODHTHRATHRBS1PR4 | |
| SCHEMBL2697754 | 0.83 | DHODH (0.53) | S1PR1DHODHTHRATHRBS1PR4 | |
| SCHEMBL248990 | 0.82 | S1PR1 (0.49) | S1PR1DHODHS1PR4S1PR5PTPN1 | |
| SCHEMBL206471 | 0.80 | S1PR1 (0.44) | S1PR1DHODHS1PR4S1PR5PTPN1 | |
| SCHEMBL206167 | 0.80 | S1PR1 (0.49) | S1PR1DHODHS1PR4S1PR5PTPN1 | |
| SCHEMBL206460 | 0.79 | S1PR1 (0.50) | S1PR1DHODHTHRATHRBS1PR4 | |
| SCHEMBL207599 | 0.79 | S1PR1 (0.56) | S1PR1DHODHTHRATHRBS1PR4 | |
| SCHEMBL208026 | 0.79 | DHODH (0.46) | S1PR1DHODHS1PR4S1PR5PTPN1 | |
| SCHEMBL208472 | 0.78 | S1PR1 (0.52) | S1PR1DHODHTHRATHRBS1PR4 | |
| SCHEMBL206224 | 0.78 | S1PR1 (0.54) | S1PR1THRATHRBS1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | PIGS, CPT1A, SLC10A1 | S1PR1 1259/4885DHODH 1219/4885THRA 928/4885 |
| US-20070004711-A1 | Thiazole compounds and methods of use | PIGS, CPT1A, SLC10A1 | S1PR1 1259/4885DHODH 1219/4885THRA 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.